Cephalon, Inc., and CIMA Labs, Inc.

Last Updated:
In the Matter of Cephalon, Inc., and CIMA Labs, Inc.
FTC Matter/File Number:


Enforcement Type:

Part 2 Consents

Case Summary

The consent order settled charges that Cephalon's proposed acquisition of Cima Labs, Inc. would allow Cephalon to continue its monopoly in the United States market for drugs that eliminate or reduce the spikes of severe pain that chronic cancer patients experience. The consent order required Cephalon to grant Barr Laboratories, Inc. a fully paid, irrevocable license to make and sell a generic version of Cephalon's breakthrough cancer pain drug, Actiq, in the United States.